AI / ML Innovations Stock Price, News & Analysis

AI/ML Innovations (AIMLF) has successfully completed an oversubscribed non-brokered private placement, raising $2,165,900 by issuing 43,318,000 units at $0.05 per unit. Each unit includes one common share and one warrant exercisable at $0.15 until April 15, 2028.

The company paid $101,815 in finder's fees and issued 1,917,300 finder's warrants. Company insiders participated significantly, with CEO Paul Duffy acquiring 4,250,000 units and President Peter Kendall purchasing 3,000,000 units. The proceeds will be used for general working capital.

Additionally, AIMLF modified terms for existing warrants from June 2023, simplifying the previous escalating exercise price structure to a fixed $0.20 exercise price for both 14,827,792 share purchase warrants and 411,800 broker warrants.

AI/ML Innovations Inc. (AIMLF) has announced updates to its non-brokered private placement offering, planning to issue up to 40,000,000 units at $0.05 per unit to raise gross proceeds of up to $2,000,000.

Each unit consists of one Common Share and one Warrant, with the Warrant term extended to three years from the previously announced two years. Warrant holders can purchase one Common Share at $0.15 per share, with no acceleration clause. The securities will have a four-month and one-day hold period.

The company plans to use the net proceeds for working capital requirements. Qualified finders assisting in unit sales will receive finder's fees in cash, securities, or both. The private placement requires approvals, including from the Canadian Securities Exchange.

AI/ML Innovations Inc. (AIMLF) has announced a non-brokered private placement offering of up to 40 million units at $0.05 per unit, aiming to raise gross proceeds of up to $2 million.

Each unit consists of one common share and one warrant. The warrants have a 2-year term and allow holders to purchase one common share at $0.15, with an acceleration clause if shares trade at $0.30 for 10 days. The securities will have a four-month and one-day hold period.

The company plans to use the net proceeds for working capital requirements. Finder's fees will be paid to qualified finders in cash, securities, or both. The private placement requires approval from the Canadian Securities Exchange.

AI/ML Innovations Inc. (AIML) has announced its strategic exit from Tech2Heal SAS (T2H) through a formal agreement dated March 21, 2025. This decision follows a previously reported impairment loss of $1,510,668 from their T2H investment in October 2024.

Under the exit agreement, AIML will relinquish its 11.11% equity position in T2H, board seat rights, and AI RX Inc.'s exclusive North American product rights. In exchange, T2H will return 1,500,000 AIML common shares for cancellation and surrender its 30% equity in AI RX Inc. Additionally, T2H's CEO Fabrice Pakin will step down from both AIML and AI RX Inc.'s boards.

The company will now focus on commercializing its core holdings: NeuralCloud Solutions Inc., Health Gauge Inc. (95.2% owned), and Quantum Sciences . This restructuring aims to optimize the utilization of AIML's human, financial, and technological resources while remaining open to future collaborations with T2H.

AI/ML Innovations Inc. (AIML) has announced significant leadership changes to drive growth and commercialization. Paul Duffy, the company's CEO, has been appointed Executive Chairman of the Board, while Peter Kendall, President and Chief Commercialization Officer, joins as a new board member. Former Executive Chair Mark Orsmond and board member Michael Nemirow have transitioned to strategic advisor roles.

These changes align with AIML's strategic focus on commercial execution, market penetration, and strategic partnerships in AI-driven healthcare technologies. Orsmond and Nemirow will continue supporting corporate development initiatives, strategic partnerships, and commercialization strategies in their advisory capacities.

AI/ML Innovations Inc. (CSE:AIML)(OTCQB:AIMLF) held its Annual General and Special Meeting where shareholders voted on key matters. A total of 54,405,656 shares (31.48% of outstanding shares) were represented. Shareholders approved the following resolutions:

- Fixed the number of directors at four
- Elected Tim Daniels, Mark Orsmond, Michael Nemirow, and Drew Dundas as directors
- Reappointed Baker Tilly WM LLP as auditor
- Approved the Company's Stock Option Plan and RSU/DSU Plan

The company focuses on artificial intelligence and machine learning in digital health through various subsidiaries and partnerships: Quantum Sciences (100% owned), NeuralCloud Solutions (100% owned), Health Gauge (95.2% owned), Tech2Heal (11.11% owned), and AI Rx (70% owned).

AI/ML Innovations Inc. (CSE:AIML)(OTCQB:AIMLF) has announced key updates to its upcoming annual general and special meeting scheduled for February 21, 2025. The company plans to increase its board seats from three to four and has nominated Dr. Drew Dundas to fill the additional position.

Dr. Dundas brings over 20 years of technology and research leadership experience, currently serving as Chief Technology Officer at Earlens His extensive background includes roles as President and CTO of Soundhawk , Director of Audiology at UCSF Medical Center, and research contributions at Starkey Hearing Technologies. He holds a PhD in Audiology & Biomedical Engineering from Vanderbilt University.

AIML focuses on artificial intelligence and machine learning in digital health through various subsidiaries and partnerships, including Quantum Sciences, NeuralCloud Solutions, Health Gauge (95.2% owned), Tech2Heal (11.11% owned), and AI Rx (70% owned).

AI/ML Innovations Inc. (CSE:AIML)(OTCQB:AIMLF) has appointed Andrea L. Ruth as Head of Quality, Clinical, and Regulatory Affairs. With over 20 years of experience in medical device and biotechnology sectors, Ruth brings expertise in regulatory compliance and quality systems implementation.

Ruth, who holds a Master of Management, has extensive experience working with global regulatory bodies including FDA and EMA. Her role will focus on maintaining safety, efficacy, and compliance standards as AIML expands its AI-driven healthcare solutions portfolio.

AIML operates in artificial intelligence and machine learning fields, focusing on digital health and wellbeing solutions. The company owns Quantum Sciences , NeuralCloud Solutions Inc., and has strategic partnerships with Health Gauge Inc. (95.2% owned), Tech2Heal (11.11% owned), and AI Rx Inc. (70% owned).

AI/ML Innovations Inc. (CSE:AIML)(OTCQB:AIMLF) has appointed Dr. Alan Rabinowitz as Chief Medical Officer and Director of Medical Partnerships. Dr. Rabinowitz brings over two decades of experience in clinical cardiology and healthcare strategy, currently serving as Clinical Associate Professor in Cardiology at UBC and previously as Director of the Coronary Care Unit at St. Paul's Hospital.

Dr. Rabinowitz's expertise spans entrepreneurial ventures in advanced diagnostics and personalized medicine, with a focus on integrating artificial intelligence in cardiology. He holds a medical degree from the University of Cape Town, with specializations from the University of Toronto and UBC.

The company also announced a stock option grant of 400,000 shares at $0.105 per share to an officer, vesting quarterly over two years. AIML focuses on AI and machine learning in digital health through various subsidiaries and partnerships, including Quantum Sciences, NeuralCloud Solutions, Health Gauge, Tech2Heal, and AI Rx.